{"id":"NCT02662985","sponsor":"Novartis Pharmaceuticals","briefTitle":"Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA)","officialTitle":"A 52-week, Multicenter Study to Assess the Time Course of Response to Secukinumab on Joint Inflammation Using Power Doppler Ultrasonography in Patients With Active Psoriatic Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-08-22","primaryCompletion":"2020-11-10","completion":"2020-11-10","firstPosted":"2016-01-26","resultsPosted":"2021-12-07","lastUpdate":"2021-12-07"},"enrollment":166,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriatic Arthritis"],"interventions":[{"type":"DRUG","name":"AIN457 (secukinumab)","otherNames":["Secukinumab"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Group 1","type":"ACTIVE_COMPARATOR"},{"label":"Group 2","type":"PLACEBO_COMPARATOR"}],"summary":"This study was designed to leverage the sensitivity of ultrasonography available in clinical practice setting to better describe the time course of response to secukinumab (150 mg and 300 mg) on joint synovitis and enthesitis in PsA patients with an inadequate response to non-biologic DMARDs. PDUS changes in joint synovitis will be assessed using the global Outcome Measures in Rheumatology (OMERACT)-European League against Rheumatism (EULAR) synovitis score (GLOESS) and changes in joint enthesitis were assessed using the OMERACT enthesitis score.","primaryOutcome":{"measure":"Difference Between Secukinumab and Placebo in Terms of Joint Synovitis as Measured by the Power Doppler Ultrasonography (PDUS) Global OMERACT-EULAR Synovitis Score (GLOESS)","timeFrame":"12 weeks","effectByArm":[{"arm":"Group 1 - Secukinumab (150 mg + 300 mg)","deltaMin":-9.05,"sd":0.94},{"arm":"Group 2 - Placebo/Secukinumab","deltaMin":-5.86,"sd":0.93}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0040"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":33,"countries":["United States","Argentina","Austria","Belgium","Canada","Colombia","Czechia","France","Germany","Hungary","Ireland","Italy","Mexico","Netherlands","Norway","Spain","United Kingdom"]},"refs":{"pmids":["34528079"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":161},"commonTop":["Nasopharyngitis","Headache","Diarrhoea","Urinary tract infection","Cough"]}}